If you’ve been Googling ways to speed up tendon, ligament, or muscle recovery, you’ve probably come across BPC-157. It’s one of the most talked-about peptides in fitness, sports, and longevity circles right now. Some people swear by it.
Others call it an outright scam. So what does the evidence actually say — and does any of it matter if you’re trying to get back to training?
Here’s the short answer: BPC-157 has shown some promising results in animal studies, but we still don’t have strong human clinical evidence that it reliably works in real patients.¹˒² If you’re dealing with an injury, the biggest driver of recovery is still an accurate diagnosis, progressive loading, and a structured rehab plan.
Let’s break it down.
What Is BPC-157?
BPC stands for Body Protection Compound. BPC-157 is a synthetic peptide — a short chain of amino acids — that was originally derived from a protein found in human gastric (stomach) juice.³ Think of peptides as small fragments of protein that can signal certain processes in the body.
It’s not an approved medication. It’s not a supplement you’ll find on a pharmacy shelf. It’s most commonly sourced through compounding pharmacies or online peptide vendors, and it’s typically taken as a subcutaneous injection (under the skin) or orally.
It’s important to know: BPC-157 is currently listed as a Category 2 substance by the U.S. FDA, meaning the agency has flagged potential safety concerns for compounding use.⁴ It’s also prohibited by WADA (the World Anti-Doping Agency), which means it’s banned in competitive sport.⁵
Why People Are Interested in BPC-157 for Injury Recovery
People usually start looking into BPC-157 when they’ve hit a wall with recovery. That typically looks like:
- A tendon issue that won’t settle — Achilles, patellar, rotator cuff
- Recurring muscle strains
- Slow recovery after surgery
- A “nothing seems to work” injury that’s been dragging on for months
If that sounds familiar, you’re not alone. The desire to find something — anything — that speeds up healing is completely understandable. That’s exactly why BPC-157 has gained so much traction online.
What the Research Says About BPC-157
This is where things get interesting — and where you need to read carefully.
What looks promising
Animal and cell-based studies have shown some encouraging signals. In lab settings, BPC-157 has been associated with:
- Accelerated tendon-to-bone healing in rat Achilles detachment models⁶
- Improved ligament healing in rats⁷
- Repair at the myotendinous junction — the point where muscle meets tendon⁸
- Muscle-to-bone reattachment after surgical detachment in rats⁹
- Wound healing, including effects on angiogenesis (the formation of new blood vessels that support tissue repair) and endothelial cell migration¹⁰
- Increased growth hormone receptor expression in tendon fibroblasts — one of the proposed mechanisms for how it might support tendon repair¹¹
That sounds exciting. And it is — at a basic science level.
What’s missing
Here’s the problem: almost all of this data comes from animal models, not human clinical trials.¹˒²
And there’s another issue worth knowing about. A large portion of the published research on BPC-157 comes from one research group, led by Professor Predrag Sikiric and close collaborators.² There are independent studies from other labs — on wound healing, pain models, and pharmacokinetics (how BPC-157 moves through the body)¹⁰˒¹¹˒¹²˒¹³ — but the literature is unusually concentrated in one research network. That doesn’t automatically mean the findings are wrong, but in science, we gain confidence when multiple independent groups replicate results. That broad replication hasn’t happened yet.
We’re also missing:
- Well-designed human randomized controlled trials (RCTs — the gold standard for testing whether a treatment works)
- Agreed-upon dosing protocols
- Long-term safety data in humans
- Evidence that BPC-157 actually improves real-world rehab outcomes
In plain terms: the animal data is interesting, but we can’t confidently say it works in people. “Promising in rats” and “proven in humans” are very different things.
The Shkreli Debate: Is BPC-157 a Scam?
In March 2026, Martin Shkreli — the controversial former pharma executive — called BPC-157 “the biggest scam I’ve ever seen” on a widely shared podcast episode.¹⁴ That clip made the rounds and reignited the debate.
Some of his points have merit. The human evidence is weak. The research is unusually concentrated in one group. And there is no approved product despite decades of study.
But some of his claims went further than the evidence supports. Saying there’s “no plausible physiological basis” for it to work isn’t quite right — there are proposed mechanisms in preclinical research, they’re just unproven in humans.¹⁰˒¹¹ And saying “nobody else has published on it” overstates the case — independent papers do exist, even if the field is dominated by one lab.¹⁰˒¹¹˒¹²˒¹³
The fairest summary: BPC-157 is underproven and surrounded by hype. Strong scepticism is warranted. But calling it a “proven scam” goes beyond what current evidence can actually confirm. We don’t have enough quality data to say it definitely works or that it definitely does nothing.
What Actually Matters for Healing
Here’s the part that matters most — whether you’re considering BPC-157 or not.
Tissues heal in response to the right mechanical signals at the right time. That’s not a sales pitch. That’s decades of well-established research in tendon, ligament, and muscle physiology.
What actually drives recovery:
- Accurate diagnosis — knowing exactly what structure is involved and what stage of healing you’re in
- Progressive loading — gradually increasing demand on the tissue so it adapts and strengthens (not resting forever, not pushing too hard too soon)
- Movement quality — making sure the surrounding joints and muscles are doing their job
- Graded return to sport or training — a structured plan that builds capacity back to where it needs to be
- Time — healing has biological timelines that no injection can skip
Even in the most optimistic reading of the BPC-157 literature, no study suggests it replaces any of the above. At best, it might theoretically support some aspect of tissue repair — but the loading, the movement, and the programming are what determine whether you actually get back to full function.
So Should You Use BPC-157?
That’s not a decision I can make for you — and it’s not something I’d prescribe in clinic. What I can tell you is this:
If you’re thinking about BPC-157, think of it as an unproven add-on, not a shortcut. The foundation of recovery is still a proper rehab plan. No peptide replaces progressive loading, good movement, and smart programming.
If you do choose to use it, be aware of the regulatory reality: it’s flagged by the FDA for safety concerns in compounding,⁴ and it’s banned in competitive sport.⁵ Quality control from online vendors is another real concern — you may not always be getting what you think you’re getting.
The Bottom Line
BPC-157 is an interesting area of research. The animal data raises real questions worth studying further. But right now, we don’t have the human evidence to call it an effective treatment — and we don’t have enough data to fully understand its safety profile either.
What we do know works: getting the right diagnosis, loading tissues correctly, progressing at the right pace, and following a structured return-to-activity plan. That’s what gets people better. That’s what my experience has found, and what the evidence supports. And that’s where your time and energy is best spent.
About the Author
Daniel da Cruz is a physiotherapist and high-performance health coach based in Sandton, South Africa. He helps high-performing, busy men and women and athletes get stronger, healthier, and more resilient — through efficient, structured programming built around how your body actually works.
Whether you’re pushing through a stubborn injury, trying to build real strength, or just tired of spinning your wheels without a proper plan, Daniel designs programmes that cut the guesswork and get results.
References
¹ Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. https://doi.org/10.1007/s00441-019-03016-8
² Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals (Basel, Switzerland), 18(2), 185. https://doi.org/10.3390/ph18020185
³ Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D., Stambolija, V., Zoricic, Z., Vrcic, H., & Sebecic, B. (2012). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry, 19(1), 126–132. https://doi.org/10.2174/092986712803414015
⁴ U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
⁵ World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org
⁶ Krivic, A., Anic, T., Seiwerth, S., Huljev, D., & Sikiric, P. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 24(5), 982–989. https://doi.org/10.1002/jor.20096
⁷ Cerovecki, T., Bojanic, I., Brcic, L., Radic, B., Vukoja, I., Seiwerth, S., & Sikiric, P. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research, 28(9), 1155–1161. https://doi.org/10.1002/jor.21107
⁸ Japjec, M., Horvat Pavlov, K., Petrovic, A., Staresinic, M., Sebecic, B., Buljan, M., Vranes, H., Giljanovic, A., Drmic, D., Japjec, M., Prtoric, A., Lovric, E., Batelja Vuletic, L., Dobric, I., Boban Blagaic, A., Skrtic, A., Seiwerth, S., & Sikiric, P. (2021). Stable gastric pentadecapeptide BPC 157 as a therapy for the disabled myotendinous junctions in rats. Biomedicines, 9(11), 1547. https://doi.org/10.3390/biomedicines9111547
⁹ Matek, D., Matek, I., Staresinic, E., Japjec, M., Bojanic, I., Boban Blagaic, A., Beketic Oreskovic, L., Oreskovic, I., Ziger, T., Novinscak, T., Krezic, I., Strbe, S., Drinkovic, M., Brkic, F., Popic, J., Skrtic, A., Seiwerth, S., Staresinic, M., Sikiric, P., & Brizic, I. (2025). Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachments for muscle-to-bone reattachment in rats. Pharmaceutics, 17(1), 119. https://doi.org/10.3390/pharmaceutics17010119
¹⁰ Huang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Jia, Z., Wang, W., Wang, C., Zhao, Y., Zak, R., & Li, J. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Burns, 41(7), 1569–1576. https://doi.org/10.1016/j.burns.2015.04.010
¹¹ Chang, C. H., Tsai, W. C., Hsu, Y. H., & Pang, J. H. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(12), 19066–19077. https://doi.org/10.3390/molecules191119066
¹² He, M. M., Feng, R., Daniel, S., Gao, Z. G., Zhang, G. L., Li, W. H., Wang, J. Y., Wang, X. Y., Mao, J. Q., & Zhang, C. L. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 13, 1026182. https://doi.org/10.3389/fphar.2022.1026182
¹³ Jung, Y. H., Kim, H., Kim, H. J., Kim, J. M., Hahm, K. B., Cho, J. Y., & Lee, Y. C. (2022). The antinociceptive effect of BPC-157 on the incisional pain model in rats. Journal of Dental Anesthesia and Pain Medicine, 22(2), 97–105. https://doi.org/10.17245/jdapm.2022.22.2.97
¹⁴ TBPN Live. (2026, March 23). The Great Peptide Debate with Martin Shkreli & Max Marchione. PodScripts transcript. https://podscripts.co/podcasts/tbpn-live/the-great-peptide-debate-with-martin-shkreli-max-marchione
¹⁵ Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Horvat Pavlov, K., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Lovric, E., Batelja Vuletic, L., Kolenc, D., Drmic, D., Strbe, S., Ilic, S., & Sikiric, P. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533
¹⁶ Sikiric, P., Seiwerth, S., Rucman, R., Drmic, D., Stupnisek, M., Kokot, A., Sever, M., Zoricic, I., Zoricic, Z., Batelja, L., Kolenc, D., Vuletic, L. B., Strbe, S., Gojkovic, S., Krezic, I., Zizek, H., Vranes, H., Sikiric, S., Lovric, E., & Brizic, I. (2025). Stable gastric pentadecapeptide BPC 157 as a therapy and safety key. Pharmaceuticals (Basel, Switzerland), 18(1), 83. https://doi.org/10.3390/ph18010083
Leave a Reply